A pill called daraxonrasib helped people with advanced pancreatic cancer live longer than chemotherapy did, across many kinds of patients, according to OncoDaily. Dr. Zev Wainberg of Los Angeles shared the new data at ESMO 2026, a major European cancer meeting, the outlet reported.

The trial, called RASolute 302, included 500 patients whose pancreatic cancer had spread and who had already been treated, OncoDaily reported. Half took daraxonrasib by mouth once a day. The other half got one of several standard chemotherapy mixes.

Earlier results from the trial showed that patients on the pill lived a median of 13.2 months, compared with 6.7 months on chemotherapy, the outlet reported. That works out to a cut of about 60% in the risk of death.

More than 90% of pancreatic cancers carry changes in a gene called RAS, which drives tumor growth, OncoDaily reported. Daraxonrasib is built to block RAS proteins that are switched on. The new data found the pill did better than chemotherapy in every group studied. That included patients with different RAS changes and patients with no RAS change found.

Some of those groups were small, and in three of them the results could have been due to chance, the outlet reported. The pill also did better no matter which chemotherapy patients were compared with, or how they had been treated before. Patients had been followed for a median of 8.5 months when the data were locked in February.

A UCLA Health news release on the analysis reports the same survival figures.

What we know: The pill extended survival in the trial across many groups of patients.
What we don't: How the results hold up with longer follow-up.